Highlights
| Issue Size – 1,77,86,442 shares | Issue Open/Close – 24 Aug / 27 Aug, 2026 |
| Price Band (Rs.) 938-988 | Issue Size (Rs.) – 17,570 mn |
| Face Value (Rs) 2 | Lot Size (shares) – 15 |
Symbiotec Pharmalab Limited (SPL) incorporated in 2002, is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients, nutritional ingredients, and specialty products. They caters to domestic and international markets across regulated and emerging regions emphasizing research-driven manufacturing, quality compliance, and sustainable processes.
SPL supports pharmaceutical, nutraceutical, and wellness industries by delivering high-quality, innovative ingredients aligned with global standards. With over 30 years of industry experience, they have evolved from a lab-scale steroidal-hormone API manufacturer into an industrial-scale, backward-integrated platform with approvals from US FDA, EU-GMP, MFDS Korea and global organisations.
SPL served over 200 customers (50 domestic and 150 export customers) across more than 40 countries. Their customer portfolio comprises key generic and specialty pharmaceutical companies across North America, Europe, and Asia, including several pharmaceutical majors and formulations companies
Out of the total proceeds of Rs. 17,570 mn, Rs. 1,125 mn would go towards prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company and Rs. 375 mn would go towards funding company’s general corporate purposes. Additionally, Rs. 16,070 mn going towards promoter and investor selling shareholders of the company.
Key Highlights
- The global pharmaceutical market, valued at USD 1.6 trillion in 2025, is projected to grow at a 6.4 pct CAGR during 2025-30 to USD 2.2 trillion, with injectables being the largest with 45.5 pct share (USD 737.1 bn) in 2025 is expected to grow at a 9.2 pct CAGR through 2030. The global API market, valued at USD 305.5 bn in 2025, is expected to grow at a 6.8 pct CAGR to USD 424.6 bn by 2030.
- SPL operates across 3 interlinked platforms – (i) Organic Chemistry, including flow chemistry, hydrogenation and photochemistry, (ii) Biotechnology, including biosynthesis, biotransformation and recombinant biologics like GLP-1 & insulin, and (iii) Complex Injectables, including double-chamber vials, bags & syringes, collectively enabling commercialisation and scaling of hard-to-replicate products and services.
- SPL benefits from high customer stickiness in complex API products due to multi-step manufacturing, stringent regulatory requirements and high switching costs involving product validation, bioequivalence studies and regulatory approvals. Its quality standards and end-to-end backward integration have supported long-standing customer relationships and increased product offerings to existing customers.
- SPL is the only Indian and global company with a presence across the top 10 corticosteroid and steroidal-hormone APIs, holding a global volume market share of 38.2 pct in corticosteroid APIs and 23.8 pct in steroidal-hormone APIs. Its market leadership is supported by a portfolio of 60 APIs, providing exposure to 90 pct of the overall corticosteroid and steroidal-hormone API market.
- SPL operates 2 industrial-scale API facilities with maximum chemical synthesis capacity of 584.67 MT, fermentation capacity of 700 KL and complex injectables capacity of 20 mn vials p.a., following commissioning of facilities at Ujjain and Mhow, enabling a vertically integrated ‘microbe-to-pharmacy’ and ‘farm-to-pharmacy’ platform with cost-efficient operations. Its biotechnology facilities are equipped with 5 KL, 35 KL and 100 KL fermenters, providing operational flexibility, while a proposed dedicated 14 KL fermentation capacity at Ujjain will further expand biologics manufacturing capacity.
- SPL’s key growth strategies include (i) To build on global leadership expanding product portfolio across steroidal-hormones in API and ingredients business, (ii) commercialize complex injectables through differentiated drug device combinations, (iii) scale up diverse CDMO offerings based on its interlinked differentiated platform technologies, (iv) continue to invest in new technologies, R&D for optimising products, building on historical innovation ethos, and (v) partner with large companies for difficult-to-execute projects.
- The sales of the company have grown by 10.16 pct CAGR over FY24-26 and EBITDA/profit has grown 14.49 pct CAGR/4.78 pct CAGR over same year. In FY26 the company reported sales of Rs. 8,692 mn rose 15.65 pct YoY. EBITDA of the company increased 12.57 pct YoY to Rs. 2,320 mn. In FY26 the company posted profit of Rs. 1,099 mn, up 13.53 pct.
Key Risk
- SPL’s manufacturing facilities are subject to periodic inspections and audits by regulatory authorities and their customers. Any manufacturing or quality control failures may trigger regulatory actions.
- SPL procures a portion of raw material requirements from China and the United States. Any adverse developments in these countries, or the laws governing imports from these countries, could disrupt SPL’s raw material supply.
- SPL benefits from incentives and schemes of the Government of India. Cancellation of such incentives and schemes, or inability to meet their conditions, may adversely affect their financial conditions.
Financial Performance
| Particulars (Rs. mn) | FY24 | FY25 | FY26 | CAGR | YoY |
| Sales | 7,163 | 7,516 | 8,692 | 10.16% | 15.65% |
| EBITDA | 1,770 | 2,061 | 2,320 | 14.49% | 12.57% |
| EBITDA Margin % | 24.71% | 27.42% | 26.69% | ||
| Profit | 1,001 | 968 | 1,099 | 4.78% | 13.53% |
| Profit Margin % | 13.98% | 12.88% | 12.64% | ||
| ROE % | 14.98% | 12.66% | 11.19% | ||
| ROCE % | 14.03% | 11.80% | 11.56% | ||
| Net Debt to EBITDA (X) | 1.37 | 2.51 | 1.64 | ||
| Fixed Asset Turnover (X) | 1.42 | 1.39 | 1.54 |
Source: – RHP.
Peer Comparison based on FY26 Financials.
| Particulars (Rs. mn) | Symbiotec Pharmalab | Divi’s Laboratories | Laurus Labs | Cohance Lifesciences | Concord Biotech |
| Sales | 8,692 | 1,05,600 | 69,129 | 22,686 | 10,549 |
| EBITDA | 2,320 | 39,200 | 18,261 | 4,320 | 3,674 |
| EBITDA Margin % | 26.69% | 37.12% | 26.42% | 19.04% | 34.83% |
| Profit | 1,099 | 25,680 | 8,901 | 1,793 | 2,592 |
| Profit Margin % | 12.64% | 24.32% | 12.88% | 7.90% | 24.57% |
| ROE % | 11.19% | 16.50% | 17.00% | 7.00% | 14.00% |
| ROCE % | 11.56% | 21.23% | 17.70% | 10.80% | 17.00% |
| Net Debt to EBITDA (X) | 1.64 | NA | 1.3 | (0.32) | NA |
Source: – RHP.
Valuation
Symbiotec is a research-driven, science-based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal Hormone Active Pharmaceutical Ingredients (APIs). With over 30 years of industry expertise, they have evolved from a Lab-Scale Steroid manufacturer into a fully integrated global platform. At the upper end of the price band of Rs. 988, the issue is priced at an PE of 57x its FY26 post issue capital. The issue appears to be fully priced. However, only high-risk investors can apply for listing gains.
Disclaimer: The views shared in blogs are based on personal opinions and do not reflect the company’s views. Investment involves risk, and it is advisable to consult a financial advisor before making any investment through the app. The decision to invest is solely that of the investor, and the company or its communication cannot be held responsible for it.
